Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MannKind ( (MNKD) ) just unveiled an announcement.
On August 24, 2025, MannKind Corporation amended its global license agreement with United Therapeutics to include an additional development product. MannKind will use its Technosphere® platform to formulate an investigational molecule and manufacture clinical trial materials, while United Therapeutics will handle preclinical and clinical development. MannKind will receive a $5 million upfront payment, up to $35 million in milestone payments, and 10% royalties on net sales if the product is approved.
The most recent analyst rating on (MNKD) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MannKind stock, see the MNKD Stock Forecast page.
Spark’s Take on MNKD Stock
According to Spark, TipRanks’ AI Analyst, MNKD is a Neutral.
MannKind’s overall score reflects strong revenue growth and strategic initiatives, such as the acquisition of scPharmaceuticals and the partnership with Blackstone. However, financial risks due to high leverage and negative equity, along with valuation concerns, weigh down the score. Technical indicators suggest mixed momentum, with short-term bullishness but longer-term bearish signals.
To see Spark’s full report on MNKD stock, click here.
More about MannKind
MannKind Corporation operates in the biopharmaceutical industry, focusing on the development and commercialization of therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. The company is known for its proprietary Technosphere® platform, which is used to formulate inhalable therapeutic products.
Average Trading Volume: 3,057,342
Technical Sentiment Signal: Sell
Current Market Cap: $1.25B
Learn more about MNKD stock on TipRanks’ Stock Analysis page.